Protagenic Therapeutics, Inc.\new (PTIX) Operating cash flow 2018–2026
Protagenic Therapeutics, Inc.\new (PTIX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$2.8MFY2026 · since FY2018: -$1.4M → -$2.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -$2.8M | -58.7% |
| FY2025 | -$1.8M | +52.2% |
| FY2024 | -$3.7M | -85.8% |
| FY2023 | -$2.0M | +28.8% |
| FY2022 | -$2.8M | -107.5% |
| FY2021 | -$1.3M | -176.4% |
| FY2020 | -$487,990 | +54.4% |
| FY2019 | -$1.1M | +22.4% |
| FY2018 | -$1.4M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More PTIX financial trends
PTIX RevenuePTIX Net incomePTIX Net marginPTIX Gross profitPTIX Gross marginPTIX Operating incomePTIX Operating marginPTIX Free cash flowPTIX Capital expendituresPTIX Return on equityPTIX Stock buybacksPTIX Dividends paidPTIX Total assetsPTIX Total liabilitiesPTIX Shareholders’ equityPTIX overview →